Zenotech Laboratories Ltd
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
- Market Cap ₹ 499 Cr.
- Current Price ₹ 81.7
- High / Low ₹ 108 / 52.2
- Stock P/E
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE -9.08 %
- ROE -12.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 5.17 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -14.8% over last 3 years.
- Debtor days have increased from 72.3 to 96.1 days.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
12 | 13 | 8 | 6 | 7 | |
15 | 19 | 18 | 24 | 16 | |
Operating Profit | -3 | -6 | -10 | -18 | -9 |
OPM % | -20% | -49% | -121% | -292% | -143% |
0 | 9 | 2 | 5 | 2 | |
Interest | 1 | 2 | 3 | 1 | 2 |
Depreciation | 0 | 2 | 3 | 3 | 3 |
Profit before tax | -3 | -1 | -14 | -18 | -13 |
Tax % | 6% | -250% | 17% | 0% | -0% |
-4 | 2 | -16 | -18 | -13 | |
EPS in Rs | 0.32 | -2.64 | -2.88 | -2.05 | |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -20% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 21% |
3 Years: | 23% |
1 Year: | 22% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -15% |
Last Year: | -12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
Equity Capital | 16 | 29 | 34 | 34 | 34 |
Reserves | 6 | 25 | 92 | 74 | 62 |
31 | 36 | 19 | 17 | 10 | |
21 | 10 | 8 | 5 | 4 | |
Total Liabilities | 74 | 100 | 153 | 131 | 111 |
16 | 60 | 61 | 62 | 71 | |
CWIP | 40 | 9 | 15 | 24 | 13 |
Investments | 0 | 0 | 0 | 0 | 0 |
19 | 30 | 77 | 45 | 27 | |
Total Assets | 74 | 100 | 153 | 131 | 111 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
-16 | -7 | -3 | -16 | -10 | |
-56 | -15 | -67 | 20 | 29 | |
74 | 22 | 70 | -4 | -8 | |
Net Cash Flow | 2 | -0 | -0 | 1 | 11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
Debtor Days | 145 | 273 | 85 | 36 | 96 |
Inventory Days | 139 | 331 | 575 | 172 | 279 |
Days Payable | 451 | 455 | 421 | 226 | 253 |
Cash Conversion Cycle | -167 | 149 | 240 | -18 | 123 |
Working Capital Days | 55 | 279 | 196 | 250 | 286 |
ROCE % | 2% | -9% | -12% | -9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Oct - Copies of Advertisement published today i.e. October 24, 2024 for the extracts of Unaudited Financial Results of the Company for the quarter and half year …
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024 And Appointment Of Dr. Sachin Laxmanappa Gavandare As Chief Executive Officer (Key Managerial Personnel) Of The Company With Immediate Effect.
23 Oct - Approval of financial results and appointment of new CEO.
-
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024
23 Oct - Appointment of Dr. Sachin Gavandare as CEO and Q2 results.
-
Board Meeting Intimation for Consideration And Approval Of Financial Results
17 Oct - Board meeting to approve Q2 financial results.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 15 Oct
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products